TWI325420B - Amino acid phenoxy ethers - Google Patents

Amino acid phenoxy ethers Download PDF

Info

Publication number
TWI325420B
TWI325420B TW093100932A TW93100932A TWI325420B TW I325420 B TWI325420 B TW I325420B TW 093100932 A TW093100932 A TW 093100932A TW 93100932 A TW93100932 A TW 93100932A TW I325420 B TWI325420 B TW I325420B
Authority
TW
Taiwan
Prior art keywords
salt
amino
dione
phenoxy
thiazolidine
Prior art date
Application number
TW093100932A
Other languages
English (en)
Chinese (zh)
Other versions
TW200418792A (en
Inventor
Bishwajit Nag
Abhijeet Nag
Debendranath Dey
Shiv Kumar Agarwal
Original Assignee
Bexel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bexel Pharmaceuticals Inc filed Critical Bexel Pharmaceuticals Inc
Publication of TW200418792A publication Critical patent/TW200418792A/zh
Application granted granted Critical
Publication of TWI325420B publication Critical patent/TWI325420B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
TW093100932A 2003-01-17 2004-01-14 Amino acid phenoxy ethers TWI325420B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44077203P 2003-01-17 2003-01-17
US10/356,113 US6794401B2 (en) 2003-01-17 2003-01-31 Amino acid phenoxy ethers

Publications (2)

Publication Number Publication Date
TW200418792A TW200418792A (en) 2004-10-01
TWI325420B true TWI325420B (en) 2010-06-01

Family

ID=32716922

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093100932A TWI325420B (en) 2003-01-17 2004-01-14 Amino acid phenoxy ethers

Country Status (20)

Country Link
US (2) US6794401B2 (enExample)
EP (1) EP1583529B9 (enExample)
JP (1) JP4833072B2 (enExample)
KR (1) KR101085315B1 (enExample)
AT (1) ATE532510T1 (enExample)
AU (1) AU2004207449A1 (enExample)
BR (1) BRPI0406772B1 (enExample)
CA (1) CA2513496C (enExample)
CY (1) CY1112673T1 (enExample)
DK (1) DK1583529T3 (enExample)
EA (1) EA200501078A1 (enExample)
ES (1) ES2374724T3 (enExample)
MA (1) MA27658A1 (enExample)
MX (1) MXPA05007684A (enExample)
NO (1) NO330984B1 (enExample)
NZ (1) NZ541328A (enExample)
PT (1) PT1583529E (enExample)
SI (1) SI1583529T1 (enExample)
TW (1) TWI325420B (enExample)
WO (1) WO2004066964A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7781464B2 (en) * 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
US7521465B2 (en) * 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
US7087576B2 (en) * 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
US7592486B2 (en) * 2004-09-16 2009-09-22 Board Of Regents Of The University Of Nebraska Anhydrous fluoride salts and reagents and methods for their production
JP2008533122A (ja) * 2005-03-18 2008-08-21 オーキッド ケミカルズ アンド ファーマシューティカルズ リミテッド 新規なチロシン誘導体
WO2007029062A2 (en) * 2005-07-29 2007-03-15 Orchid Research Laboratories Limited Novel pyridine derivatives
US7989480B2 (en) 2006-08-04 2011-08-02 Decode Genetics Ehf Aryl amino acid derivatives as inhibitors for treating inflammation
KR20100037047A (ko) * 2007-06-26 2010-04-08 렉시컨 파마슈티컬스 인코퍼레이티드 세로토닌-매개 질환 및 장애의 치료 방법
AU2008275179B2 (en) 2007-07-11 2013-09-12 Lexicon Pharmaceuticals, Inc. Methods and compositions for treating pulmonary hypertension and related diseases and disorders
WO2009030968A1 (en) * 2007-09-05 2009-03-12 Orchid Research Laboratories Limited Mao a inhibitors with a diphenyl ether-substructure.
ATE536347T1 (de) 2008-05-20 2011-12-15 Merck Sharp & Dohme Effiziente herstellung heterologer proteine unter verwendung von mannosyltransferaseinhibitoren
US20140187594A1 (en) 2010-07-28 2014-07-03 Orchid Chemicals And Pharmaceuticals Ltd Diphenyl ether compounds for the treatment of liver, lung disorders, diabetic complications and cardiovascular diseases
WO2012153775A1 (ja) 2011-05-10 2012-11-15 国立大学法人神戸大学 Ras機能阻害作用を有するチオキソチアゾリジン誘導体

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020049240A1 (en) * 1994-12-19 2002-04-25 Beecham Group P.1.C. Novel compounds
US5166137A (en) * 1991-03-27 1992-11-24 Nobipols Forskningsstiftelse Guluronic acid polymers and use of same for inhibition of cytokine production
US5441971A (en) * 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
ATE185564T1 (de) * 1992-08-31 1999-10-15 Sankyo Co Oxazolidin-derivate mit antidiabetika und anti- fettleibigkeit-eigenschaften, ihre herstellung und therapeutische verwendung
TW268952B (enExample) * 1993-02-26 1996-01-21 Takeda Pharm Industry Co Ltd
CA2171827C (en) * 1993-09-15 2004-06-29 Jerrold Olefsky Use of thiazolidinediones to prevent or delay onset of niddm
US5527546A (en) * 1994-08-10 1996-06-18 Bayer Corporation Human interleukin 6 inhibitor
DE4432101A1 (de) * 1994-09-09 1996-03-14 Hoechst Ag Aminosäure-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
WO1996035782A1 (en) * 1995-05-11 1996-11-14 Applied Research Systems Il-6 activity inhibitor
IL118474A (en) * 1995-06-01 2001-08-08 Sankyo Co Benzimideol derivatives and pharmaceutical preparations containing them
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
TW577875B (en) * 1997-01-31 2004-03-01 Shionogi & Co Pyrrolidine derivatives with inhibitory activity for phospholipase A2
JPH11124331A (ja) * 1997-08-21 1999-05-11 Takeda Chem Ind Ltd 抗炎症剤
US6331633B1 (en) * 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
US6699896B1 (en) * 1998-05-12 2004-03-02 Wyeth Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
HUP0103082A3 (en) * 1998-06-05 2002-12-28 Astrazeneca Ab Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
KR100613175B1 (ko) * 1998-08-27 2006-08-17 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체 및 그 유도체를 유효 성분으로서함유하는 약제
PT1177187E (pt) 1999-04-28 2007-09-03 Sanofi Aventis Deutschland Derivados ácidos de di-arilo como ligados do receptor ppar.
TWI284533B (en) * 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
WO2001002377A1 (en) 1999-07-01 2001-01-11 Geron Corporation Telomerase inhibitors and methods of their use
AU778720B2 (en) * 1999-08-23 2004-12-16 Kyorin Pharmaceutical Co. Ltd. Substituted benzylthiazolidine-2,4-dione derivatives
US6515003B1 (en) * 1999-08-31 2003-02-04 Maxia Pharmaceuticals, Inc. Heterocyclic derivatives for the treatment of diabetes and other diseases
JP2001199888A (ja) * 2000-01-24 2001-07-24 Fujimoto Brothers:Kk 糖尿病治療剤
JP2001294537A (ja) * 2000-02-10 2001-10-23 Takeda Chem Ind Ltd 併用医薬
DE60115132T2 (de) 2000-04-21 2006-07-06 Pfizer Products Inc., Groton Thyroid-Rezeptorliganden
US6680387B2 (en) * 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis

Also Published As

Publication number Publication date
DK1583529T3 (da) 2012-01-23
KR101085315B1 (ko) 2011-11-22
ES2374724T3 (es) 2012-02-21
NZ541328A (en) 2008-11-28
EP1583529A2 (en) 2005-10-12
WO2004066964A2 (en) 2004-08-12
BRPI0406772A (pt) 2005-12-27
ATE532510T1 (de) 2011-11-15
NO330984B1 (no) 2011-08-29
KR20050092764A (ko) 2005-09-22
WO2004066964A9 (en) 2004-09-02
JP4833072B2 (ja) 2011-12-07
WO2004066964A3 (en) 2005-02-24
TW200418792A (en) 2004-10-01
US6794401B2 (en) 2004-09-21
NO20053714L (no) 2005-10-11
MXPA05007684A (es) 2006-03-10
MA27658A1 (fr) 2005-12-01
BRPI0406772B1 (pt) 2016-08-23
NO20053714D0 (no) 2005-08-01
JP2007501288A (ja) 2007-01-25
EP1583529A4 (en) 2007-07-04
PT1583529E (pt) 2012-02-13
SI1583529T1 (sl) 2012-02-29
EA200501078A1 (ru) 2006-02-24
CY1112673T1 (el) 2016-02-10
US20050096366A1 (en) 2005-05-05
CA2513496A1 (en) 2004-08-12
EP1583529B9 (en) 2012-04-04
AU2004207449A1 (en) 2004-08-12
EP1583529B1 (en) 2011-11-09
CA2513496C (en) 2013-05-14
US20040142991A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
TWI325420B (en) Amino acid phenoxy ethers
KR20050087786A (ko) 신규한 디페닐에틸렌 화합물의 헤테로사이클릭 동족체
WO2024063140A1 (ja) Ｇｌｐ－１受容体アゴニスト作用を有する単環化合物
JP5414280B2 (ja) 新規複素環式ジフェニルエーテル
JP5134974B2 (ja) 血漿中のグルコースレベル、コレステロールレベル及びトリグリセリドレベルを低下させるための５−［４−（４−（２−アミノ−２−メトキシカルボニルエチル）フェノキシ）ベンジリデン］チアゾリジン−２，４−ジオン誘導体及び関連化合物
AU2008285663A1 (en) N-(2-thiazolyl)-amide derivatives for the treatment of obesity, diabetes and cardiovascular diseases
Pardeshi et al. Synthesis, Antidiabetic Evaluation and Molecular Docking Studies of Thiazolidine-2, 4-Dione Analogues
JP2008535904A (ja) 新規複素環誘導体
KR20080025662A (ko) 신규 티로신 유도체
ZA200506527B (en) Amino acid phenoxy ethers
CN117203211A (zh) 咪唑并噻唑衍生物及其制备方法与应用
JPH10182461A (ja) 内臓脂肪減少剤
CN101160296A (zh) 用于降低血浆中葡萄糖、胆固醇和甘油三酸酯水平的5-[4-(4-(2-氨基-2-甲氧基羰基乙基)苯氧基)亚苄基]噻唑烷-2，4-二酮衍生物和相关化合物
JP2007230868A (ja) 二環性化合物及びそれを用いた医薬

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees